NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

bb2121

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7)

KarMMa-7

Relapsed & Refractory Multiple Myeloma

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM.

The following combinations will be

Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone)

Arm B will test bb2121 in combination with BMS-986405 (JSMD194)

Arm C will test bb2121 in combination with one of the following standard triplet regimens:

1) Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (DPd)

2) Pomalidomide (POM) in combination with bortezomib (BTZ) and low-dose dexamethasone (PVd)

Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion.

The study will consist of 2 parts:

dose finding (Phase 1) and dose expansion (Phase 2).

Dose expansion may occur in one or more arms.

Sponsor